Withdrawn trial patterns
Withdrawn clinical trials rarely show biological failure signals
Only 98 of 6,821 withdrawn records (1.4%) carry efficacy/futility or safety signals. Withdrawn status alone is weak evidence of drug failure.
- The current database contains 6,821 withdrawn clinical trial records.
- 98 withdrawn records, or 1.4%, are classified as likely biological failure signals.
- 34 withdrawn records carry efficacy/futility signals and 64 carry safety signals.
- Operational reasons account for 3,168 withdrawn records, while 3,515 are classified as other or unknown.
- Other is the largest withdrawn disease-area slice with 1,958 records.
The headline result
Withdrawn is one of the three stopped statuses covered by this database, alongside terminated and suspended. It is also one of the easiest labels to over-interpret. Only 98 of 6,821 withdrawn records (1.4%) carry stop language classified as efficacy/futility or safety.
Most withdrawn records fall into operational (3,168) or other/unknown (3,515) classifications. That does not make them unimportant. It means the status field alone is weak evidence for the claim that a drug, target, or biological hypothesis failed.
Why withdrawal often happens before evidence exists
A withdrawn study may never begin enrollment, may fail to activate sites, may lose funding, or may be abandoned after a sponsor or investigator decision. In those cases, the intervention may never have received a meaningful clinical test.
This is different from a trial that enrolls patients and stops after a futility analysis, missed endpoint, or safety concern. Both records are stopped, but the evidence content is not comparable.
Why other or unknown is so common
ClinicalTrials.gov stop explanations vary enormously. Some are detailed and explicit. Others are short, administrative, or absent. A large other/unknown bucket therefore reflects both genuine ambiguity and limitations in the source text.
I would rather keep an unclear record visibly unclear than force it into efficacy or safety. That makes the database more conservative, even though it produces a less satisfying headline classification.
The small scientific subset still matters
A minority of withdrawn records does contain efficacy or safety language. Those cases deserve attention because they differ from the dominant withdrawal pattern. They should be opened individually and checked against enrollment history, dates, endpoints, sponsor disclosures, and the source record.
The right interpretation is not that withdrawn trials never contain biological evidence. It is that biological evidence is unusual enough within this status group that it should be demonstrated, not assumed.
How I would review a withdrawn trial
I would start by checking whether anyone was enrolled. Next I would read the official why-stopped field, compare the start and update dates, inspect the phase, and identify whether the sponsor described an operational, strategic, efficacy, or safety reason.
If the record contains only a generic explanation, I would avoid a failed-drug label. A more accurate description may be withdrawn before enrollment, withdrawn for feasibility, withdrawn by sponsor decision, or withdrawn for an unclear reason.
What this result cannot prove
This analysis does not prove that the interventions in withdrawn trials work. Absence of an efficacy or safety failure signal is not evidence of success. It often means that the available record does not support either conclusion.
The database is a screening and research tool. It helps separate the strength of the available stop signal, but final interpretation still requires the original registry entry and any associated primary documents.
Withdrawn trial stop-reason mix
| Reason classification | Withdrawn records |
|---|---|
| Other/unknown | 3,515 |
| Operational | 3,168 |
| Safety | 64 |
| Regulatory | 40 |
| Efficacy/futility | 34 |
Largest withdrawn phase groups
| Phase | Withdrawn records |
|---|---|
| Phase II | 2,076 |
| Phase I | 1,153 |
| Phase IV | 1,012 |
| Phase III | 825 |
| Unknown | 666 |
| Phase I + Phase II | 607 |
| Early Phase I | 270 |
| Phase II + Phase III | 212 |
Largest withdrawn disease-area slices
| Disease area | Withdrawn records |
|---|---|
| Other | 1,958 |
| Oncology | 1,805 |
| Infectious Disease | 602 |
| Gastroenterology & Hepatology | 441 |
| Cardiovascular | 413 |
| Neurology | 267 |
| Endocrine & Metabolic | 255 |
| Immunology & Autoimmune | 210 |
Continue from here
FAQ
Does withdrawn mean a clinical trial failed?
Not by itself. A withdrawn trial may stop before enrollment or for operational, funding, strategic, or unclear reasons. The source explanation must be reviewed before drawing a biological conclusion.
Can a withdrawn trial contain a safety or efficacy signal?
Yes, but those signals are a small minority in the current withdrawn-trial slice. They should be verified individually against the original registry record and related documents.
Does no biological failure signal mean the intervention worked?
No. It only means the available stop language was not classified as efficacy/futility or safety. It is not evidence of clinical success.
Source note: counts are generated from the current ClinicalTrials.gov-derived stopped-trial dataset used by ClinicalTrialFailures.com. These labels are analytical screening signals, not medical advice.